BUSINESS ACQUISITIONS & DISPOSITIONS Business Acquisitions (Tables)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The purchase price allocations for these acquisitions were preliminary at December 31, 2024. The valuation of acquired assets and assumed liabilities include the following:

	Baystate Medical Center		Providence Medical Foundation		Westpac Labs, Inc.		Invitae Corp.		BioReference Health		Other Business Acquisitions		Measurement Period Adjustments		Amounts Acquired During the Year Ended December 31, 2024
Inventories	$	—	$	—	$	1.8	$	12.1	$	—	$	—	$	2.0	$	15.9
Prepaid expenses and other	—		—		—		—		—		—		8.4		8.4
Property, plant and equipment	7.2		0.9		—		76.7		9.1		1.3		28.1		123.3
Goodwill	70.7		25.9		45.1		100.4		107.4		41.0		(90.6)		299.9
Intangible assets	79.8		29.2		50.8		113.2		121.1		46.2		44.3		484.6
Total assets acquired	157.7		56.0		97.7		302.4		237.6		88.5		(7.8)		932.1
Accrued expenses and other	—		—		—		—		—		—		(3.9)		(3.9)
Unearned revenue	—		—		—		3.3		—		—		(3.3)		—
Lease liabilities	7.2		0.9		—		58.3		—		0.6		—		67.0
Total liabilities acquired	7.2		0.9		—		61.6		—		0.6		(7.2)		63.1
Net assets acquired	150.5		55.1		97.7		240.8		237.6		87.9		(0.6)		869.0
Less 2023 escrow payment	30.0		—		—		—		—		—		—		30.0
Cash paid for acquisitions	$	120.5	$	55.1	$	97.7	$	240.8	$	237.6	$	87.9	$	(0.6)	$	839.0

The purchase price allocations for these acquisitions were preliminary at December 31, 2023. The preliminary valuation of acquired assets and assumed liabilities, include the following:

	Jefferson Health		Enzo BioChem		Providence Health and Services - Oregon		Tufts Medicine		Legacy		Other Business Acquisitions		Measurement Period Adjustments		Amounts Acquired During the Year Ended December 31, 2023
Accounts receivable	$	—	$	(2.8)	$	—	$	—	$	—	$	2.0	$	0.2	$	(0.6)
Inventories	—		—		1.3		—		—		—		—		1.3
Prepaid expenses and other	—		0.4		—		—		0.2		0.3		0.6		1.5
Property, plant and equipment	—		—		4.7		—		3.3		6.5		(1.5)		13.0
Goodwill	50.8		54.1		50.7		73.8		49.0		18.5		(29.4)		267.5
Intangible assets	57.2		61.1		57.2		83.2		55.2		26.9		19.5		360.3
Other assets	2.2		—		—		—		—		17.9		—		20.1
Total assets acquired	110.2		112.8		113.9		157.0		107.7		72.1		(10.6)		663.1
Accounts payable	—		—		—		—		—		1.2		—		1.2
Accrued expenses and other	—		—		3.9		—		—		1.2		(8.3)		(3.2)
Deferred income taxes	—		—		—		—		—		—		(2.3)		(2.3)
Other liabilities	—		—		—		—		—		(4.1)		—		(4.1)
Total liabilities acquired	—		—		3.9		—		—		(1.7)		(10.6)		(8.4)
Net assets acquired	$	110.2	$	112.8	$	110.0	$	157.0	$	107.7	$	73.8	$	—	$	671.5

A summary of the net assets acquired in 2022 for these businesses is included below:

	Preliminary Personal Genome Diagnostics Inc.		Preliminary Ascension Healthcare		Other Acquisitions		Measurement Period Adjustments		Amounts Acquired During Year Ended December 31, 2022
Accounts receivable	$	4.1	$	—	$	(1.3)	$	(2.3)	$	0.5
Unbilled services	2.9		—		—		(3.2)		(0.3)
Inventories	2.5		24.6		—		—		27.1
Prepaid expenses and other	1.2		0.4		0.3		—		1.9
Property, plant and equipment	9.9		43.5		0.1		—		53.5
Deferred income taxes	17.5		—		—		15.2		32.7
Goodwill	346.8		125.0		126.7		(40.4)		558.1
Intangible assets	136.6		233.2		172.5		30.4		572.7
Other assets	12.5		—		2.3		(2.3)		12.5
Total assets acquired	534.0		426.7		300.6		(2.6)		1,258.7
Accounts payable	3.8		—		—		(0.1)		3.7
Accrued expenses and other	57.3		—		15.4		0.1		72.8
Unearned revenue	3.3		—		—		(2.6)		0.7
Lease liabilities	—		2.9		—		—		2.9
Other liabilities	14.6		—		—		—		14.6
Total liabilities acquired	79.0		2.9		15.4		(2.6)		94.7
Net assets acquired	$	455.0	$	423.8	$	285.2	$	—	$	1,164.0

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information [Table Text Block]

Had the aggregate of the Company’s 2024 acquisitions been completed at January 1, 2023, the Company’s pro forma results would have been as follows:

	Year Ended December 31,
	2024		2023
Revenues	$	13,353.6	$	12,716.4
Net earnings attributable to LHI	$	761.8	$	423.3

Had the aggregate of the Company’s 2023 acquisitions been completed at January 1, 2022, the Company’s pro forma results would have been as follows:

	Year Ended December 31,
	2023		2022
Revenues	$	12,350.1	$	12,126.3
Earnings from continuing operations	$	397.2	$	1,030.3

Had the aggregate of the Company’s 2022 acquisitions been completed at January 1, 2021, the Company’s pro forma results would have been as follows:

	Year Ended December 31,
	2022		2021
Revenues	$	11,984.7	$	13,325.7
Earnings from continuing operations	$	1,006.8	$	2,182.4